TOBI^® and  BETHKIS^® are aerosolized forms of the antibiotic tobramycin, which is used to treat people with CF who are chronically infected with Pseudomonas aeruginosa. 

Status

The FDA approved TOBI® in 1997 and BETHKIS® 2012 . 

Sponsor

The TOBI® program was sponsored by Novartis Pharmaceuticals and funded by the Cystic Fibrosis Foundation. The BETHKIS® program was sponsored by Cornerstone Therapeutics. Both programs were conducted within the Therapeutics Development Network.